Product Description
ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of several immune-mediated diseases. (Sourced from: https://www.abbvie.com/our-science/pipeline/abbv-668.html)
Mechanisms of Action: RIPK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Poland, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Colitis, Ulcerative
Phase 1: Healthy Volunteers